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Abstract
Rationale: Asthma has substantial morbidity and mortality and a strong genetic component, but identification of genetic
risk factors is limited by availability of suitable studies.
Objectives: To test if population-based cohorts with self-reported physician-diagnosed asthma and genome-wide
association (GWA) data could be used to validate known associations with asthma and identify novel associations.
Methods: The APCAT (Analysis in Population-based Cohorts of Asthma Traits) consortium consists of 1,716 individuals with
asthma and 16,888 healthy controls from six European-descent population-based cohorts. We examined associations in
APCAT of thirteen variants previously reported as genome-wide significant (P,5x1028) and three variants reported as
suggestive (P,561027). We also searched for novel associations in APCAT (Stage 1) and followed-up the most promising
variants in 4,035 asthmatics and 11,251 healthy controls (Stage 2). Finally, we conducted the first genome-wide screen for
interactions with smoking or hay fever.
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Main Results: We observed association in the same direction for all thirteen previously reported variants and nominally
replicated ten of them. One variant that was previously suggestive, rs11071559 in RORA, now reaches genome-wide
significance when combined with our data (P= 2.461029). We also identified two genome-wide significant associations:
rs13408661 near IL1RL1/IL18R1 (PStage1+Stage2 = 1.1x10
29), which is correlated with a variant recently shown to be associated
with asthma (rs3771180), and rs9268516 in the HLA region (PStage1+Stage2 = 1.1x10
28), which appears to be independent of
previously reported associations in this locus. Finally, we found no strong evidence for gene-environment interactions with
smoking or hay fever status.
Conclusions: Population-based cohorts with simple asthma phenotypes represent a valuable and largely untapped
resource for genetic studies of asthma.
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Introduction
Asthma, characterized by episodic breathlessness, chest tight-
ness, coughing and wheezing, is estimated to affect 300 million
people worldwide [1] and is associated with morbidity and
economic costs that are comparable with other common chronic
diseases [2,3]. As with many common diseases, asthma risk is
determined by both genetic and environmental factors, and
estimates of heritability (the proportion of variability in risk within
a population due to inherited factors) range from 35 to 90% in
twin studies [4,5,6]. However, only a handful of genetic variants
have thus far been validated as associated with asthma risk at
stringent levels of statistical significance.
The first genome-wide association (GWA) study for asthma [7]
was conducted in 2007, with 994 child-onset asthmatics and 1,243
non-asthmatics. This study implicated a locus near ORMDL3 – a
gene not previously suspected to have a role in asthma
susceptibility. Although the initial association did not reach a
widely used threshold for genomewide significance in discovery
samples (P,561028), the association was subsequently replicated,
including numerous independent studies, particularly in Europe-
an-derived and Hispanic populations [8,9,10,11]. Subsequent
GWA studies of asthma identified variants in PDE4D [12] and
DENND1B [13] associated with asthma at genome-wide significant
levels, although the proposed variant in DENND1B showed
considerable heterogeneity of associations between different
populations. In a GWA study of severe asthma, two other loci
narrowly missed genome-wide significance [14]: one in the HLA
region, and one near RAD50, (a locus previously shown to be
associated with total IgE levels) [15]. A GWA study of eosinophil
counts with follow-up testing in asthma case-control studies
identified variants near IL1RL1/IL18R1 and IL33 as being
associated with asthma [16]. More recently, a meta-analysis of
23 GWA studies by the GABRIEL consortium [17] studied 10,365
physician-diagnosed asthmatics and 16,110 participants without
asthma. They observed associations with asthma, particularly
childhood-onset asthma, at multiple loci (ORMDL3/GSDMB,
IL1RL1/IL18R1, HLA-DQ, IL33, SMAD3, and IL2RB). Several
additional loci in this study narrowly missed the genome-wide
significance threshold. Most recently, GWA studies in largely non-
European ancestries [18,19] confirmed some of the loci discovered
in Europeans, and identified additional associations at PYHIN1,
USP38-GAB1, an intergenic region of 10p14, and a gene-rich
region of 12q13. A very recent GWA study of severe asthma in
Europeans found strong evidence for two previously established
loci (ORMDL3/GSDMB and IL1RL1/IL18R1) in patients with
severe asthma but did not identify any novel loci [20].
Many of the above findings have come from GWA studies on
samples specifically established for the investigation of allergy and
asthma, often with rich phenotypic information on asthma and
related diseases. While such detailed phenotypic information is
extremely valuable, collection of such samples is resource-
intensive, potentially limiting the sample size. As for all other
polygenic traits, sample sizes of current GWA studies of asthma
are a limiting factor in the search for genetic risk factors [21].
Expanding GWA studies to include additional cohorts that may
APCAT
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not have such detailed phenotypic information could increase the
power to detect associations.
One route to increasing power may be found in the numerous
population-based cohorts with existing genome-wide genotype
data that also have basic information on doctor-diagnosed asthma,
but have not been comprehensively analyzed for associations with
asthma. The idea of reanalyzing existing GWA data is similar to
the approach adopted by consortia studying quantitative traits that
are routinely measured in many studies, such as height and weight
[22,23]. However, unlike anthropometric measures, asthma is a
disease where diagnostic criteria may not always be consistent
[24,25,26]. As such, it is uncertain whether the rather minimal
phenotype of a self-report of doctor-diagnosed asthma is sufficient
to be useful in genetic studies of asthma.
In this paper, we test whether a self-report of doctor-diagnosed
asthma in population-based cohort could be used to replicate
findings previously reported by other asthma GWA studies or
identify novel genetic associations with asthma. To achieve this
aim, we formed the Analysis in Population-based Cohorts for
Asthma Traits (APCAT) genetics consortium, which currently
includes 18,604 adults of European ancestry (1,716 cases and
16,888 controls) from six population-based cohorts with GWA
data. To study further the top hits emerging from the meta-
analyses of APCAT (Stage 1), we utilized in-silico replication data
(Stage 2) from 15,286 adults of European ancestry (4,035 cases and
11,251 controls). We were able both to replicate known signals and
to identify new associations, indicating that genetic studies of
asthma in population-based cohorts are likely to be useful
complements to more focused studies of asthma.
Results
The APCAT genetics consortium includes 1,716 individuals
with asthma diagnosed (ever) by a physician, and 16,888 non-
asthmatic controls, from six population-based cohorts (Table 1).
Genome-wide genotyping was conducted on available platforms
and, after standard quality control (see Methods), subsequently
imputed to ,2.5 million autosomal SNPs using the HapMap
CEU reference panel (Table S1). Association studies with asthma
used an additive genetic model and were adjusted for sex,
ancestry-informative principal components and (in non-birth
cohorts) for age; we also controlled for relatedness in family-based
cohorts. We meta-analyzed the study-specific results using a fixed
effect model and considered ,2.2 million SNPs with imputation
quality .0.30 and minor allele frequency .5%. We applied
genomic control at the individual study level and again after meta-
analysis to correct for inflation of test statistics due to any
systematic bias. The individual study genomic control inflation
factors were modest (lGC #1.02 for all studies; Table S1). We
also explored whether stratifying the individual cohorts by
smoking status or by the presence of allergic symptoms prior to
meta-analysis substantially affected our results. We observed
strong correspondences between the unstratified and stratified
analyses (Figure S1), and therefore primarily report on the
unstratified results as a simpler main analysis with slightly
improved power.
Analysis of genetic variants previously associated with
asthma
To test whether the population-based cohorts and the
phenotype of self-reported doctor-diagnosed asthma could be
used to detect associations, we analyzed thirteen SNPs in nine
genomic loci that had shown genome-wide significant associations
in previously published GWA studies of European ancestry
individuals. Encouragingly, the APCAT results (Table 2) are
directionally consistently for all thirteen SNPs, and nominally
replicate (one-tailed P,0.05) ten of these thirteen SNPs. We were
unable to assess the PYHIN1 variant reported as associated with
asthma in African-Americans [18] as this variant is monomorphic
in European populations. For variants discovered in Japanese
individuals [19,27], it is harder to interpret replication in our
samples because of differences in LD. Nevertheless, we examined
the associations in APCAT for the reported lead SNPs and
additional SNPs in LD in the HapMap JPT sample. For two out of
the four loci, the associations showed directional consistency, with
one association nominally replicated (rs1701704 in IKZF4,
p = 0.00132, see Table S2).
We also examined three SNPs where previous evidence was
strongly suggestive (P,561027 for association with asthma) but
not genome-wide significant (Table 2), and one of them,
rs11071559 in RORA, is strongly supported in our data (Reported
P=1.1x1027; PAPCAT =0.0031). The combined evidence of
association at RORA (P=2.461029) now surpasses the genome-
wide significance threshold, and therefore rs11071559 represents a
new genome-wide significant association with asthma. We note
that the RORA locus is 6.4 Mb away from a known asthma variant
(rs744910 near SMAD3), but these two loci are independent,
because there is low linkage disequilibrium between these two
variants (pairwise linkage disequilibrium, r2 = 0.01 in HapMap
CEU panel) and because the association estimates for these two
variants are virtually unchanged when conditioned on each other
(Table S3).
Search for novel asthma risk loci in APCAT
Having established the validity and utility of our population-
based studies, we next examined the results of a genome-wide
meta-analysis of the studies within APCAT (Figure S2), with the
goal of identifying novel associations with asthma. An inspection of
the quantile-quantile plots (Figure S2) and the low genomic
inflation factor (l=1.01) of the meta-analyses indicate that there is
little evidence of confounding by population stratification or other
technical artifacts.
To test whether some of the top results from the APCAT
analysis could represent valid associations with asthma, we
considered the most strongly associated 14 SNPs from indepen-
dent loci within the APCAT results (Stage1 in Table 3). We
obtained in silico replication data for 14 top SNPs from several
additional studies of asthma, including two population based
cohorts. These replication studies consisted of the 1958 British
Birth Cohort (B58C), Australian Asthma Genetics Consortium
(AAGC), the second survey of the European Community
Respiratory Health Survey (ECRHS2) and the European
Prospective Investigation of Cancer in Norfolk (EPIC-Norfolk)
(Table S1). The results from the replication studies (Stage2) and a
meta-analysis of these results with the APCAT data (Stage 1 +
Stage 2) are summarized in Table 3.
The most strongly replicated SNP is rs13408661 near the
IL1RL1 and IL18R1 genes, with the combined P value reaching
genome-wide significance (PStage1 = 3.9610
26; PStage2
= 3.261025; PStage1+Stage2 = 1.1610
29; Figure 1). This SNP lies
approximately 31.1 kb from rs3771166 (pairwise r2 = 0.157)
identified by GABRIEL [17] and 2.6 kb from rs1420101
(r2 = 0.053) identified by an earlier study [16] as genetic risk
factors for asthma. Conditioning rs13408661 on either rs3771166
or rs1420101 did not substantially reduce the signal of association
in APCAT (Table S3), implying that rs13408661 represents a
different signal of association at this locus. Interestingly, a previous
study focusing on previously reported risk loci for asthma in a
APCAT
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subsample of the Australian samples in this report [8] had also
suggested that an association with rs10197862, which is tightly
correlated with rs13408661 (r2 = 0.932), was independent of other
associated variants in the region. Quite recently, a study of
ethnically diverse sample of Americans [18] identified a genome-
wide significant association at rs3771180/rs10173081, which are
also tightly correlated with rs13408661 (r2 = 0.907 and 1).
Therefore, the combined data, including our conditional analyses,
indicate that rs13408661 truly represents an additional genome-
wide significant signal of association with asthma at this locus.
Our second strongest signal is at rs9268516 (PStage1 =
1.261027; PStage2 = 1.0610
23; PStage1+Stage2 = 1.1610
28;
Figure 2) in the HLA region on Chromosome 6, approximately
246 kb away from the rs9273349 variant (r2 = 0.324) identified by
GABRIEL [17]. Conditional analysis (Table S3) indicates that
the association at rs9273349 cannot completely explain the
association at rs9268516, suggesting either the presence of multiple
signals at this locus or the presence of a third variant (partially
correlated with both rs9273349 and rs9268516) that explains the
association at both of these variants.
None of the other variants had compelling evidence of
replication in our Stage2 data (Table 3), although rs7861480 near
IFNE showed a trend in the same direction (P=0.064). We also
examined the evidence for association of these 14 SNPs or their
proxies in the GABRIEL data (estimates downloaded from http://
www.cng.fr/gabriel/results.html), excluding B58C and ECRHS
(which participated in Stage2 of the APCAT study) and the
occupational asthma cohorts. Consistent with our Stage2 results, we
saw directionally consistent evidence of association at rs13408661
(P=7.0610–6) in the IL1RL1/IL18R1locus and rs9268516 in the
HLA region (P=0.069); rs7861480 near IFNE showed directional
consistency but was not significantly associated with asthma in
GABRIEL (P=0.19).
We also estimated the variance explained in the APCAT by the
most strongly associated SNP at each of the previously reported
loci. Under a liability threshold [28], and assuming a prevalence of
9% (the prevalence in APCAT), these SNPs together explain
,1.6% of the population variance in asthma risk (Table S4). Of
course, additional variance is explained by multiple signals at each
locus (such as at IL1RL1/IL18R1and HLA regions), variants at
additional loci (such as at RORA), and variants yet to be
discovered by additional genetic studies.
Search for interactions with smoking and allergic status
in APCAT
To our knowledge, there has been no genome-wide search for
gene-environment interactions with smoking status or allergic
status, two important modifiers for risk of developing asthma. We
scanned ,2.2 million SNPs for gene-environment effects for
smoking exposure in APCAT by comparing, for each SNP, the
estimated association statistics with asthma in current smokers to
the estimates in never smokers. The strongest evidence for
interaction with smoking status did not reach genome-wide
significance [estimated pooled odds ratio for interaction between
rs1007026 (nearest genes are MOCS1 and DAAM2) and smoking
status = 1.89; 95% confidence interval 1.43 to 2.49,
Table 2. Results in APCAT for SNPs at loci with strong previously published evidence of association with asthma.
Loci with previous genome-wide significant associations to asthma (P,561028)
Reported APCAT APCAT+Reported
Gene in regiona SNP Studyb
Effect
Allelec OR (95% CI) P value OR (95% CI) P valued OR (95% CI) P valuee
GSDMA, GSDMB, ORMDL3 rs3894194 1 A 1.17 (1.11,1.23) 4.6E-09 1.11 (1.04,1.18) 2.3E-03 1.15 (1.10,1.19) 1.4E-10
rs2305480 1 A 0.85 (0.81,0.90) 9.6E-08 0.94 (0.87,1.01) 4.1E-02 0.89 (0.84,0.93) 1.6E-07
rs7216389 2 T 1.18 (1.11,1.25)f 8.5E-08f 1.11 (1.04,1.19) 2.1E-03 1.15 (1.11,1.20) 2.6E-09
IL33 rs3939286 3 T 1.12 (1.07, 1.17) 5.3E-06 1.18 (1.10,1.26) 4.8E-05 1.13 (1.09,1.18) 3.6E-09
rs1342326 1 C 1.20 (1.13,1.28) 9.2E-10 1.18 (1.09,1.28) 2.5E-04 1.2 (1.15,1.25) 2.0E-12
HLA-DQ rs9273349 1 C 1.18 (1.13,1.24) 7.0E-14 1.22 (1.07,1.38)g 5.6E-03g 1.19 (1.14,1.23) 2.8E-15
IL18R1, IL1RL1 rs3771166 1 A 0.87 (0.83,0.91) 3.4E-09 0.89 (0.82,0.97) 2.4E-03 0.88 (0.84,0.92) 7.0E-11
rs1420101 3 T 1.16 (1.11, 1.21) 5.5E-12 1.16 (1.08,1.23) 9.9E-05 1.16 (1.12,1.20) 4.9E-15
SMAD3 rs744910 1 A 0.89 (0.86,0.92) 3.9E-09 0.92 (0.85,1.00) 1.7E-02 0.90 (0.86,0.93) 5.7E-10
IL2RB rs2284033 1 A 0.89 (0.86,0.93) 1.2E-08 0.98 (0.91,1.06) 3.1E-01 0.91 (0.88,0.95) 1.4E-07
IL13 rs1295686I 1 C 0.87 (0.83,0.92) 1.4E-07 0.90 (0.82,0.98) 5.4E-03 0.88 (0.84,0.92) 5.9E-09
DENND1B rs2786098 4 T 0.70 (0.63,0.78) 3.9E-11 0.93 (0.89,1.02) 5.8E-02 0.83 (0.76,0.90) 4.7E-08
PDE4D rs1588265 5 G 0.85 (0.87,0.93) 2.5E-08 0.96 (0.85,1.06) 2.0E-01h 0.87 (0.82,0.92) 1.1E-07
Loci with previous suggestive associations to asthma (P,561027)
RORA rs11071559 1 T 0.85 (0.80,0.90) 1.1E-07 0.86 (0.75,0.97) 3.1E-03 0.85 (0.80,0.91) 2.4E-09
RAD50 rs2244012 6 G 1.64 (1.36,1.97) 3.0E-07 1.05 (0.96,1.14) 1.3E-01 1.14 (1.06,1.22) 1.5E-03
SLC22A5 rs2073643 1 C 0.90 (0.87,0.94) 2.2E-07 0.96 (0.88,1.04) 1.6E-01 0.91 (0.88,0.95) 3.9E-07
aGene shown is nearest gene to associated SNP. SNPs from the same locus are grouped together. bReferences: 1 =Moffatt et al. (2010) [17]; 2 =Moffatt et al. (2007) [7];
3 = Gudbjartsson et al. (2009) [16]; 4 = Sleiman et al (2010) [13]; 5 =Himes et al (2009) [12]; 6 = Li et al. (2010) [22]. cAlleles are indexed to the forward strand of NCBI
build36. dAPCAT P values are one-tailed with respect to the direction of the original association. eP values are from fixed-effect inverse-variance model of meta analysis.
fResults shown are from Moffatt et al (2010), which is the larger and more recent study. g SNP rs9273349 is present in NFBC1966 data set only. hResults exclude the
Framingham Heart Study, which contributed to the original report in Himes et al (2009) IShown here are the random effects P value in Gabriel data, the P value for fixed
effects model had a genome wide significance P value of 1.4E-08 with no evidence of heterogeneity.
doi:10.1371/journal.pone.0044008.t002
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Figure 1. Regional association and forest plots for rs13408661 in the IL1RL1/IL18R1 locus. For the regional plot, the lead SNP is indicated
by a purple diamond, and the degree of linkage disequilibrium (r2) of other SNPs in the region to the lead SNP is indicated by the color scale. Genes
are shown below, and estimated recombination rate is indicated by the blue lines. Note that the regional plot is based on Stage1 (pooled) estimates
only. For the forest plot, the estimated odds ratio and 95% confidence interval for each individual study is shown by the boxes (scaled to sample size)
and lines; pooled estimates and 95% confidence intervals are indicated by diamonds.
doi:10.1371/journal.pone.0044008.g001
Figure 2. Regional association and forest plots for rs9268516 in the HLA region, with symbols as in Figure 1.
doi:10.1371/journal.pone.0044008.g002
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P=8.661026; Figure S3]. Similarly, we scanned for interactions
with allergic status in APCAT by comparing, for each SNP, the
estimated association statistics for asthma in individuals with hay
fever (the most commonly available measure of allergic risk factors
in the APCAT studies) to the estimates in individuals without hay
fever. The locus with the strongest evidence of interaction with
allergic status did not reach genome-wide significance either
[estimated pooled odds ratio for interaction between rs17136561
(located in SLC22A23 which overlaps with PSMG4 and
TUBB2B) and hay fever status = 1.64; 95% confidence interval
1.33 to 2.02, P=2.361026; Figure S3]. We did not pursue either
of these loci further.
We also investigated whether the associations of the previously
known or suggestive loci, and the signals emerging from this paper
(rs13408661 near the IL1RL1/IL18R1 genes and rs9268516 in the
HLA region), differed in association by smoking or allergic status.
The direction of association for asthma in the never smokers and
also in non-allergic individuals (i.e. the healthy subgroups) were
generally consistent with the unstratified analysis, but with weaker
signals as expected with reduced sample sizes (Table S5). A
formal test for heterogeneity between smoking strata indicated no
significant differences. Similarly, there was no significant hetero-
geneity for the allergic strata except possibly for rs2284033 in
IL2RB (Pheterogeneity = 0.038), where opposite directions of
association with asthma were observed in the two allergic strata,
and for rs11071559 in RORA (Pheterogeneity = 0.059) where the
signal for asthma association appears to be seen predominantly in
the allergic individuals.
Materials and Methods
Participants and Studies
Cases and controls for the discovery study were drawn from six
population-based studies of individuals of European ancestry:
FINRISK [29], Framingham Heart Study [30], Health 2000 [31],
Helsinki Birth Cohort [32], Northern Finland Birth Cohort of
1966 [33] and Young Finns Study [34]. All cohorts were
genotyped using commercially available genotyping arrays and
SNPs which passed QC filters were used to impute up to
2.5 million SNPs using HapMap CEU as the reference. Partic-
ipants for the in silico replication were drawn from the 1958 British
Birth Cohort (B58C) [7], the Australian Asthma Genetics
Consortium (AAGC) [35], European Community Respiratory
Health Survey followup (ECRHS) [36] and EPIC-Norfolk [37].
Study characteristics are given in Table 1 and Supplementary
Methods; genotyping and imputation details are given in
Table S1. The most strongly associated SNPs from APCAT
were checked for validity after re-analysis of data from the
GABRIEL (A Multidisciplinary Study to Identify the Genetic and
Environmental Causes of Asthma in the European Community)
study [17] (excluding B58C, ECRHS2 and cohorts with occupa-
tional asthma) made available at www.cng.fr/gabriel (Table 3).
Phenotype definition and stratification
Cases were defined as individuals who had given an affirmative
questionnaire response to the question ‘‘Have you ever been
diagnosed with asthma?’’ (exact wording varied among question-
naires – see Supplementary Methods). The remaining subjects
served as healthy controls if they did not affirmatively respond to
any of the following: self-reported asthma without a physician
diagnosis, chronic obstructive pulmonary disease, emphysema,
chronic bronchitis, chronic cough associated with wheeze, other
lung disease, or FEV1 ,70% of predicted. Individuals with reports
of chronic obstructive pulmonary disease, emphysema, chronic
bronchitis, or other lung diseases were also excluded from the
cases.
We also conducted two stratified analyses of asthma: smoking-
stratified and allergy-stratified. Allergic status was defined using an
affirmative response to the question ‘‘Have you ever had hay fever
or other allergic nasal symptoms?’’ (exact wording varied among
questionnaires), as this was the most uniformly available informa-
tion on allergy in APCAT. Participants were divided into three
smoking categories: never smokers, ex-smokers if smoked regularly
more than a year ago or current smokers if currently smoking or
smoked regularly in past year.
Statistical analyses
The association statistic for each SNP oriented towards the
forward strand and was calculated assuming an additive genetic
model adjusting for sex, ancestry-informative principal compo-
nents, and (in non-birth cohorts) for age. In the family-based
Framingham Heart Study, the association analysis was done
controlling for family structure using the GWAF package in R
[38]. The data for FINRISK, Health 2000, the Helsinki Birth
Cohort, and the Young Finns Study were analyzed together with
an adjustment term for cohort. The data from this combined
dataset along with data from the Framingham Heart Study and
the Northern Finland Birth Cohort of 1966 were meta-analyzed
and verified using the fixed effect inverse-variance method
implemented in METAL [39] and R. Genomic control was
applied at the individual study level as well as in meta-analysis
stage. Approximately 2.2 million SNPs with imputation quality
(info) .0.30 and minor allele frequency (MAF) .5% were
analyzed.
SNP selection for in silico replication
We selected a locus (defined as a region 500 kb wide) for further
follow-up if it either contained a single SNP with P,1026 or
multiple SNPs with P,1025. The ‘‘sentinel SNP’’ was defined as
the SNP with the most significant P value and was included in the
replication list.
Discussion
We completed a genome-wide association study of a simple
asthma phenotype – self-report of ever having been diagnosed by a
physician with asthma – from 18,604 participants from six
population-based studies comprising the APCAT consortium.
We performed follow-up analyses of the top signals from APCAT
in 15,286 additional individuals. These results provided strong
evidence for an additional associated variant in the HLA region, a
known asthma locus, and confirmed recent reports of multiple
associations at the IL1RL1/IL18R locus. We also examined the
evidence for association in APCAT of SNPs with previous
genome-wide or suggestive evidence of asthma, and show that
the results from our population-based studies validate and in one
case newly establish genome-wide significant associations with
asthma. Finally, we found no evidence of genes modifying the
relation between smoking and asthma or the relationship between
hay fever and asthma.
The present study has several strengths. First, it demonstrates
the usefulness of a large untapped resource to complement genetic
studies of asthma: population-based studies with genome-wide
genotype data and a simple asthma phenotype: self-reported
information on doctor-diagnosed asthma. We also present the first
comprehensive search for genetic interactions with smoking status
and with hay fever, two important modifiers of asthma develop-
ment. Finally, we provide evidence for new genome-wide
APCAT
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significant associations with asthma: one novel signal where there
was prior suggestive evidence of association (RORA), one
independent novel signal at a previously associated locus (the
HLA region), and one previously associated locus where we
demonstrate multiple independent signals (IL1RL1/IL18R1).
It is important to recognize some limitations of this present
study. First, the constituent studies in APCAT studies have limited
information on asthma, such as age of asthma onset or severity of
symptoms, which prevents a more detailed investigation of
associated loci. Second, although controls were carefully selected
to exclude individuals with other respiratory diseases or abnor-
malities on spirometry (see methods) that may share pleiotropic
risk alleles with asthma, the choice of controls in population-based
cohorts is potentially subject to misclassification bias due to the
inclusion of undiagnosed cases among the controls. We note that
this problem is common to many study designs for diseases with
variable age at onset such as asthma, but does not prevent the
identification of new disease markers. Third, the power to detect
novel associations in population based studies is restricted by the
low prevalence of disease (our prevalence was ,9%) compared to
a case-control study of an equivalent total sample size and an equal
number of cases to controls. However, we note that the large
number of additional available population-based studies similar to
the ones in APCAT still represent a large untapped pool of
genotyped cases. Fourth, we only examined SNPs with frequencies
above 5%, so have not tested rarer variants for association to
asthma. Finally, the use of self-reported diagnosis of asthma in the
APCAT cohorts, even though it was doctor-diagnosed, may also
have led to misclassification within cases.
Despite these limitations, we were able to independently
validate 10 of 13 SNPs previously reported as being associated
for asthma through GWA studies, which indicates that population-
based studies with simple asthma phenotypes can indeed
complement ongoing genetic studies in asthma. For most (but
not all) of these variants, the estimated effect sizes in APCAT are
smaller than reported, which could be due to the ‘‘winner’s curse’’
phenomenon [40], slightly greater misclassification in our cohorts,
or other differences between this study and previous reports.
However, the fact that most of the APCAT odds ratios fall within
the 95% confidence intervals of the original reports and the p-
values typically becomes more significant when combined with the
APCAT data suggests that the power gained by adding
population-based studies still outweigh the effects of any misclas-
sification there may be. When the reported estimates are
combined with our data, the variant rs11071559 in RORA reaches
genomewide significance. In the subsequent analysis, the associ-
ation in RORA was perhaps more strongly associated with asthma
in individuals with hay fever. This gene belongs to a subfamily of
nuclear orphan receptors suggested to negatively regulate inflam-
matory response [41]. Interestingly, RORA deficient mice have
diminished capacity to mediate allergic inflammatory response
[41,42,43]. A recent paper found that RORA is critical for the
development of nuocytes, which are part of the innate immune
response and contribute to asthma response, in mice [44] Another
recent study that looked at asthma candidate genes found that
RORA is differentially expressed during lung development in both
mouse and human [45].
By analyzing the results of meta-analysis of APCAT studies, we
identified and successfully replicated associations of rs13408661 in
the IL1RL1/IL18R1 region and of rs9268516 in the HLA region;
the association with rs13408661 is in agreement with recent
findings [8,18]. These two loci had originally been reported to
contain other strongly associated variants [16,17], which we now
show are distinct from the ones we identify. Observing multiple
signals at a locus could either be due to multiple true causal
variants, as seen in genetic studies for height and other polygenic
traits [22,46], or due to a single causal variant that is not well
tagged by either signal. While fine mapping of data in these
regions would be required to resolve this problem conclusively, we
note that the variants we identified were only modestly correlated
with published variants and remain significant even after
conditioning on known risk variants. Thus, our data provide two
genome-wide significant signals of association at known loci that
are distinct from the first variants originally reported to be
associated with asthma at genome-wide significance, and in one
case (HLA) is not accounted for by the known associations.
Finally, we present the first comprehensive search for genetic
interactions with smoking status and with hay fever, two
potentially important modifiers of asthma development. In our
studies, we found no convincing evidence for SNPs that interacted
with either smoking or hay fever. A larger meta-analysis would be
required to confirm the absence or existence of such gene-
environment effects for asthma.
In conclusion, these results strongly suggest that GWA studies of
population-based cohorts with simple asthma phenotypes are an
effective approach to find novel asthma-associated variants,
replicate signals identified in other studies, and provide estimates
that are representative of the demography and disease spectrum.
Such cohorts are an untapped resource that can be utilized to
complement genetic studies of asthma. We anticipate that many
more population-based studies could be leveraged to assist with
discovery of asthma susceptibility loci, which could potentially lead
to more effective or targeted therapies and preventions.
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